Experts recommend universal diabetes testing for pregnant women at first prenatal visit

(Press-News.org) Contact information: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Experts recommend universal diabetes testing for pregnant women at first prenatal visit Endocrine Society publishes Clinical Practice Guideline on diabetes and pregnancy Chevy Chase, MD—The Endocrine Society today issued a Clinical Practice Guideline (CPG) to help health care professionals provide the best care to pregnant women who have diabetes.

The CPG, entitled "Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline" appeared in the November 2013 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.

Experts acknowledge that cases of diabetes in pregnant women are being missed by traditional screening methods, said Ian Blumer, MD, of the Charles H. Best Diabetes Centre in Whitby, Ontario, Canada, and chair of the task force that authored the guideline. The Endocrine Society CPG recommends that all pregnant women who have not been previously diagnosed with diabetes be tested for the condition at their first prenatal visit. The test should be done before 13 weeks' gestation or as soon as possible thereafter.

"Many women have type 2 diabetes but may not know it," Blumer said. "Because untreated diabetes can harm both the pregnant woman and the fetus, it is important that testing for diabetes be done early on in pregnancy so that if diabetes is found appropriate steps can be immediately undertaken to keep both the woman and her fetus healthy."

As many as one in five women may develop gestational diabetes – a form of diabetes that has its onset during pregnancy. Traditional testing strategies only identify about a quarter of these cases. This means that many women go undiagnosed and are at increased risk of having an overly large baby, which can complicate delivery.

"To address this problem, the CPG advocates for using lower blood glucose levels to diagnose gestational diabetes," Blumer said. "Using these lower levels will allow for the detection of gestational diabetes in many women when it would otherwise go undetected using the older diagnostic thresholds. Once the diagnosis is made, treatment can be given to help the fetus grow normally."

"Thanks to important new studies of the interplay between diabetes and pregnancy, diabetes specialists and obstetricians have identified best practices for caring for pregnant women with this condition," Blumer added. "The guideline synthesizes evidence-based strategies to support women who have diabetes during pregnancy."

Other recommendations from the CPG include:

All pregnant women who have not previously been diagnosed with diabetes should be tested for gestational diabetes by having an oral glucose tolerance test performed at 24-28 weeks' gestation;

Weight loss is recommended prior to pregnancy for women with diabetes who are overweight or obese;

Initial treatment of gestational diabetes should be medical nutrition therapy and daily moderate exercise lasting at least 30 minutes;

If lifestyle therapy is not sufficient to control gestational diabetes, blood glucose-lowering medication should be added;

Women with gestational diabetes should have an oral glucose tolerance test six to 12 weeks after delivery to rule out prediabetes or diabetes;

Women who have had gestational diabetes with a previous pregnancy need to be tested for diabetes regularly, especially before any future pregnancies; and

Women who have type 1 or type 2 diabetes should undergo a detailed eye exam to check for diabetic retinopathy, and, if damage to the retina is found, have treatment before conceiving.

The Hormone Health Network has published a fact sheet on gestational diabetes. The resource is available at http://www.hormone.org/questions-and-answers/2012/gestational-diabetes.

### Other members of The Endocrine Society task force that developed this CPG include: Eran Hadar of Helen Schneider Hospital for Women in Petach Tikva, Israel; David R. Hadden of Royal Victoria Hospital in Belfast, Northern Ireland; Lois J. Jovanovič of Sansum Diabetes Research Institute in Santa Barbara, CA; Jorge H. Mestman of the University of Southern California in Los Angeles; M. Hassan Murad of the Mayo Clinic in Rochester, MN; and Yariv Yogev of Helen Schneider Hospital for Women.

The Society established the CPG Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each CPG is created by a task force of topic-related experts in the field. Task forces rely on scientific reviews of the literature in the development of CPG recommendations. The Endocrine Society does not solicit or accept corporate support for its CPGs. All CPGs are supported entirely by Society funds.

Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.